Alector IncNASDAQ:ALEC
- LAST PRICE4.4100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.0500/ 10
- Ask / Lots7.0200/ 1
- Open / Previous Close0.0000 / 4.4100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALEC |
|---|---|---|
| 09:32 ET | 2999 | 4.31 |
| 09:34 ET | 200 | 4.32 |
| 09:36 ET | 400 | 4.37 |
| 09:38 ET | 907 | 4.385 |
| 09:39 ET | 300 | 4.38 |
| 09:43 ET | 1100 | 4.3671 |
| 09:45 ET | 600 | 4.41 |
| 09:48 ET | 300 | 4.4 |
| 09:50 ET | 351 | 4.4 |
| 09:52 ET | 200 | 4.39 |
| 09:54 ET | 700 | 4.375 |
| 09:56 ET | 100 | 4.39 |
| 09:57 ET | 2505 | 4.39 |
| 09:59 ET | 300 | 4.38 |
| 10:01 ET | 191 | 4.41 |
| 10:03 ET | 200 | 4.41 |
| 10:06 ET | 1400 | 4.4 |
| 10:08 ET | 914 | 4.43 |
| 10:10 ET | 1072 | 4.42 |
| 10:12 ET | 500 | 4.44 |
| 10:14 ET | 300 | 4.48 |
| 10:15 ET | 580 | 4.48 |
| 10:17 ET | 400 | 4.4821 |
| 10:19 ET | 200 | 4.51 |
| 10:21 ET | 400 | 4.51 |
| 10:24 ET | 1960 | 4.5103 |
| 10:26 ET | 2191 | 4.511 |
| 10:28 ET | 1300 | 4.5 |
| 10:30 ET | 1289 | 4.49 |
| 10:32 ET | 725 | 4.499 |
| 10:33 ET | 600 | 4.5 |
| 10:35 ET | 2500 | 4.5 |
| 10:37 ET | 300 | 4.5 |
| 10:39 ET | 162 | 4.5 |
| 10:42 ET | 300 | 4.51 |
| 10:44 ET | 2596 | 4.49 |
| 10:46 ET | 397 | 4.4816 |
| 10:48 ET | 2000 | 4.475 |
| 10:51 ET | 400 | 4.48 |
| 10:53 ET | 1000 | 4.47 |
| 10:55 ET | 370 | 4.47 |
| 10:57 ET | 1702 | 4.45 |
| 11:00 ET | 562 | 4.45 |
| 11:02 ET | 1718 | 4.455 |
| 11:04 ET | 500 | 4.47 |
| 11:06 ET | 100 | 4.465 |
| 11:08 ET | 1600 | 4.44 |
| 11:11 ET | 2378 | 4.459 |
| 11:13 ET | 200 | 4.45 |
| 11:15 ET | 1763 | 4.44 |
| 11:18 ET | 828 | 4.449 |
| 11:20 ET | 300 | 4.44 |
| 11:24 ET | 584 | 4.44 |
| 11:26 ET | 200 | 4.45 |
| 11:27 ET | 1133 | 4.43 |
| 11:29 ET | 1563 | 4.43 |
| 11:31 ET | 100 | 4.43 |
| 11:33 ET | 378 | 4.43 |
| 11:36 ET | 300 | 4.44 |
| 11:38 ET | 500 | 4.43 |
| 11:40 ET | 500 | 4.425 |
| 11:42 ET | 1133 | 4.415 |
| 11:44 ET | 300 | 4.4 |
| 11:45 ET | 300 | 4.395 |
| 11:47 ET | 12650 | 4.405 |
| 11:49 ET | 901 | 4.42 |
| 11:51 ET | 1525 | 4.41 |
| 11:54 ET | 591 | 4.39 |
| 11:56 ET | 5750 | 4.4 |
| 11:58 ET | 14721 | 4.42 |
| 12:00 ET | 300 | 4.43 |
| 12:02 ET | 700 | 4.44 |
| 12:03 ET | 300 | 4.43 |
| 12:05 ET | 600 | 4.44 |
| 12:07 ET | 771 | 4.43 |
| 12:09 ET | 300 | 4.44 |
| 12:12 ET | 300 | 4.44 |
| 12:14 ET | 1700 | 4.425 |
| 12:16 ET | 1362 | 4.41 |
| 12:18 ET | 1488 | 4.395 |
| 12:20 ET | 973 | 4.405 |
| 12:23 ET | 100 | 4.405 |
| 12:25 ET | 1324 | 4.42 |
| 12:27 ET | 1052 | 4.42 |
| 12:30 ET | 1370 | 4.415 |
| 12:32 ET | 300 | 4.415 |
| 12:34 ET | 2607 | 4.415 |
| 12:36 ET | 619 | 4.42 |
| 12:38 ET | 400 | 4.415 |
| 12:39 ET | 500 | 4.42 |
| 12:41 ET | 1600 | 4.405 |
| 12:43 ET | 900 | 4.415 |
| 12:45 ET | 2745 | 4.415 |
| 12:48 ET | 300 | 4.42 |
| 12:50 ET | 400 | 4.415 |
| 12:52 ET | 2004 | 4.425 |
| 12:54 ET | 1400 | 4.44 |
| 12:56 ET | 1641 | 4.44 |
| 12:57 ET | 6120 | 4.42 |
| 12:59 ET | 45670 | 4.41 |
Jun 20, 2024
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow JonesDJ Alector Price Target Maintained With a $35.00/Share by HC Wainwright & Co., from 6:29AM ET on Thursday Jun 20, 2024 by Dow Jones
6:29AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 10, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alector Inc | 425.1M | -3.2x | --- |
Grail Inc | 411.3M | -0.3x | --- |
Regenxbio Inc | 532.9M | -1.8x | --- |
Y-mAbs Therapeutics Inc | 499.4M | -22.9x | --- |
Editas Medicine Inc | 383.2M | -2.2x | --- |
Heron Therapeutics Inc | 417.3M | -4.5x | --- |
Company Information
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
Contact Information
- Headquarters
- 131 OYSTER POINT BLVD., SUITE 600SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-231-5660
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- Louis Lavigne
- President, Head - Research and Development
- Saraswati Kenkaremitra
- Chief Executive Officer, Co-Founder, Director
- Arnon Rosenthal
- Chief Financial Officer
- Marc Grasso
- Chief Business Officer
- Neil Berkley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $425.1M |
|---|---|
Revenue (TTM) | $96.4M |
Shares Outstanding | 96.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-1.39 |
Book Value | $1.58 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -150.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
